Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Condition(s):Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple MyelomaLast Updated:July 24, 2017Terminated
Hide Studies Not Open or Pending
Condition(s):Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple MyelomaLast Updated:July 24, 2017Terminated
Condition(s):CataractLast Updated:August 23, 2023Completed
Condition(s):Diabetic Macular Edema; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic RetinopathyLast Updated:March 30, 2021Completed
Condition(s):Pseudophakic Cystoid Macular Edema,; Diabetic Macular EdemaLast Updated:October 4, 2012Completed
Condition(s):CataractLast Updated:September 22, 2022Not yet recruiting
Condition(s):Glaucoma Following SurgeryLast Updated:November 11, 2021Not yet recruiting
Condition(s):HealthyLast Updated:June 1, 2015Completed
Condition(s):CataractLast Updated:September 8, 2023Withdrawn
Condition(s):Corneal Edema; Corneal Defect; Anterior Chamber Inflammation; Ocular Pain; Corneal Staining; Visual Outcome; CME – Cystoid Macular EdemaLast Updated:July 24, 2023Recruiting
Condition(s):Non-infectious Anterior UveitisLast Updated:June 11, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.